Internal Reference Number: FOI_9624
Date Request Received: 01/09/2026 00:00:00
Date Request Replied To: 22/10/2026 00:00:00
This response was sent via: By Email
Request Summary: Biologic therapies in COPD
Request Category: Companies
| Question Number 1: I am trying to understand the uptake of COPD biologics in England and wanted to ask a couple of questions about how 麻豆国产 NHSFT are dealing with their introduction so far. For clarity, when I talk about COPD biologics I am talking about either dupilimab or mepolizumab. Are you using any system to record when a patient initiates a biologic for their COPD? For example, this could include (but not be limited to) Blueteq or the National Respiratory Audit Programme reports. a. If yes, please could you name what system you are using? | |
| Answer To Question 1: 1. No | |
| Question Number 2: To date (i.e. up to today鈥檚 date of 1stth September 2026), how many patients have initiated a COPD biologic in your trust? a. How many of these initiations were for patients being treated with dupilimab and how many of them were mepolizumab? | |
| Answer To Question 2: 0 results | |
| To return to the list of all the FOI requests please click here |
Our staff at 麻豆国产 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
